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doi:10.1016/j.ijsu.2010.05.005Background: High circulating platelet counts have been associated with poor prognosis in a variety of
solid tumours such as breast, renal and lung cancer. We investigated the signiﬁcance of a high pre-
operative platelet count on overall survival in patients with stages IeIV colorectal cancer.
Patients and methods: 630 Consecutive patients who colorectal cancer resection between 2004 and 2007
with a full blood count taken 14 days prior to the surgery were assessed. Male:female 7:5, median (range)
age 73 (40e99 years). Thrombocytosis was deﬁned as platelet count of 450  109/L. The relationship
between platelet count, pathological features and overall survival was assessed.
Results: : ManteleCox regression showed that platelet count does not predict survival on multivariate
analysis (p ¼ 0.067). Thrombocytosis was present in 51/627 (8.1%) of cases. There was no statistically
signiﬁcant difference in mean survival (p ¼ 0.067) observed in patients with platelet count <450  109/L
(n ¼ 576; 95%CI: 1550.5e1405.4 SE 37.0) versus 450  109/L (n ¼ 51, CI: 1261.6e955.0, SE 78.2). There
was also no correlation between Dukes stage and thrombocytosis.
Conclusion(s): In our study, pre-operative thrombocytosis is not a prognostic indicator of survival in
colorectal cancer patients regardless of pathological stage.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Colorectal adenocarcinoma is a very common tumour and
a leading cause of cancerdeath in theUK.1,2 Surgical resection remains
the only option for long-term survival. Multiple factors signiﬁcantly
affect survival in resected patients, including lymph node status,
resection margins, tumour differentiation, and adjuvant treatment.
Various studies have associated thrombocytosis with poor
survival in breast,3 gastric, oesophageal,4 colorectal,5 pancreatic,
renal,6e8 gynaecologic,9 and lung malignancies.10 Thrombocytosis
may be excited by proteolysis of the basement membrane and neo-
angiogenesis, processes common in colorectal cancer.11e13 Throm-
bocytosis has been evaluated in colorectal cancer, but the results
have been often conﬂicting and have included limited patient
numbers. The aim of the present study was to evaluate the prog-
nostic relevance of pre-operative platelet count in a large cohort of
patients with resected colorectal cancer.ne and Health, University of
Medicine and Health, Derby
2 3DT, UK. Tel.: þ44 1332 724
gham.ac.uk (S.M.Nyasavajjala).
ciates Ltd. Published by Elsevier Lt2. Methods
We performed a retrospective review of 629 consecutive
patients presenting with pathologically proven colorectal cancer
between Jan 2004 and Dec 2007. Demographic, surgical, pathologic,
and laboratory variables were collected. Patients who were diag-
nosed with colorectal cancer during the study period were identi-
ﬁed from a database of colorectal cancer patients. All patients,
including those who did not undergo any surgical procedure were
included. The database is prospectively maintained and all patients
are followed-up regularly by a team of colorectal nurse specialists.
Age, sex, mode of presentation (emergency or elective), Dukes
stage, TNM Classiﬁcation and neo-adjuvant therapy were recorded
for all patients.
Thrombocytosis was deﬁned as platelet count of 450  109/L.
All the patients were followed-up for at least 18 months post-
operatively by the time of data collection. Overall survival and
cancer-speciﬁc survival were recorded.2.1. Statistical analysis
Results are presented as either median (with range) or mean
(with standard deviation) for non-parametric and parametric data
respectively. Chi-square was used for categorical variables andd. All rights reserved.
Table 1
Summary of patient demographics.
Parameter Number of patients (%)
Age 73 (40e99) years
(Median (range))
Site of tumour
Colon 288 (46%)
Rectum 341 (54%)
Dukes’ stage
A 72 (11.4%)
B 294 (46.7%)
C 212 (33.8%)
D 15 (2.4%)
In-situ 36 (5.7%)
Table 3
Platelet count of patients stratiﬁed according to Dukes staging.
Dukes stage Mean survival in weeks N Std. Deviation
A 240.06 71 73.207
B 307.30 294 115.991
C 292.26 175 113.423
D 320.87 15 65.124
Total (overall) 295.36 592 110.930
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continuous variables with parametric or non-parametric distribu-
tions, respectively, after exploration analysis of normality. Potential
prognostic factors were entered into univariate KaplaneMeier
models of intercurrent death and cancer-speciﬁc death and
compared by the log-rank test in order to identify potential prog-
nostic factors. Signiﬁcant prognostic factors identiﬁed from the
univariate analysis were entered into a multivariate ManteleCox
regression model of survival to test for independence. The 5% level
was considered signiﬁcant.
3. Results
3.1. Patients
A total of 629 patients met the inclusion criteria (2 patient data
unavailable), male:female 7:5; patient demographics are shown in
Table 1. Thrombocytosis was deﬁned as platelet count of
450  109/L. Overall median (range) age was 73 (40e99 years).
Median age of patients with platelets <450  109/L e 71.94 years
and those with platelets >450  109/L was 72.4 years. The rela-
tionship between platelet count, pathological features and overall
survival was assessed in a multivariate model. At the last follow-up
(31 July 2009) median time period of follow-up was 22 months
(range 9e60), 474/627 patients (75.6%) were alive; and 153/627
(24.4%) had died.
3.2. Survival
Overall survival stratiﬁed by Dukes stage is shown in Table 2.
ManteleCox regression showed that platelet count is not an inde-
pendent marker of survival on multivariate analysis (p ¼ 0.067).
Thrombocytosis was observed in 51/627 (8.1%) of cases and its
presence was not associated with extramural vascular invasion
(p ¼ 0.058, Fisher’s Exact Test).
All the survival data collected as part of our study passed
normality tests. A detailed analysis of platelet count stratiﬁed by
Dukes stage is shown in Table 3. Patients with thrombocytosis didTable 2
Overall survival of patients with resected colorectal adenocarcinoma (measured to
31 July 2009).
Dukes stage Mean survival in months Std. Error 95% Conﬁdence interval
Lower bound Upper bound
A 55.277 2.299 50.771 59.783
B 53.238 1.445 50.405 56.070
C 46.662 1.637 43.454 49.871
Overall 51.961 1.055 49.893 54.028not have any signiﬁcant difference in overall mean survival, (CI:
1384.74, 1067.25 SE 80.99, p ¼ 0.067, ManteleCox). There is no
statistically signiﬁcant difference in mean survival (p ¼ 0.067)
(Fig. 1) observed in patients with platelet count <450  109/L
(n¼ 576 of 627; 95%CI: 1550.5e1405.4 SE 37.0) versus450 109/L
(n¼ 51 of 627, CI: 1261.61e955.05, SE 78.2, ManteleCox) (Fig. 2). By
univariate analysis, Dukes staging, T staging, metastatic lymph
nodes, and vascular invasion were associated with poor survival
(Table 4).4. Discussion
The presence of thrombocytosis in some solid tumours has been
associated with poor prognosis. The state of cancer is strongly
associated with hypercoagulability, which is due to direct inﬂuence
of the cancer cells themselves and various indirect mechanisms not
fully explained by releasing endothelial and tumour cell-based
proteolytic enzymes, thrombocytosis contributes to the process of
proteolysis of basement membrane.12,14 Due to unknown mecha-
nisms, several studies noted an increased platelet count in the
presence of malignancy, often thought of as a paraneoplastic
syndrome. This study shows no relationship between pre-operative
platelet count and survival.
Previous smaller studies reported association between platelet
count and survival. Monreal et al. (1998)5 found that in their cohort
of 180 consecutive patients, a high pre-operative platelet level (RR:
2.467; 95%C.I.: 1.117e5.452) independently predicted poor prog-
nosis. In another study, Tweedle et al.15 (398 patients) found that
thrombocytosis was observed in 39/398 (9.8%) of cases and its
presence was associated with extramural vascular invasion, depth
of tumour invasion and lymph node involvement. They also
reported a signiﬁcant reduction in survival of patients with
thrombocytosis from 41 months to 15 months in those withoutet
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Fig. 1. Box-whisker plot showing survival in patients with higher and lower pre-
operative platelet count.
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Fig. 2. Platelet count stratiﬁed by the event of death.
Table 4
Clinicopathological characteristics and survival.
Factor Chi-Square df Sig.
T Category 14.423 1 .0001
N Category 8.880 1 .003
Dukes stage 8.377 1 .004
Vascular invasion 2.891 1 0.046
Thrombocytosis 9.261 1 0.067
S.M. Nyasavajjala et al. / International Journal of Surgery 8 (2010) 436e438438(p < 0.0001, ManteleCox). These ﬁndings were not supported in
our larger series of patients.
In summary, this large cohort of patients with adenocarcinoma
of the colon and rectum, with complete follow-up shows no
statistical evidence to support that pre-operative platelet count is
an adverse prognostic factor. The follow-up period for patients with
colorectal cancer in our study is limited. Although a longer follow-
up (>5years) or higher platelet cut-offs could potentially show
a difference in survival, the number of patients needed to demon-
strate this would be very large. In our series of over 600 patients,
we have demonstrated a lack of association between thrombocy-
tosis and survival from colorectal cancer.Conﬂict of interest
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